Study evaluates accuracy of CPS compared to gold-standard right heart catheterization to support FDA submission
Sensydia, a medical technology company pioneering non-invasive cardiac assessment, announced that the first patient has been enrolled in its multi-center pivotal study to evaluate the accuracy of the Cardiac Performance System (CPS) for hemodynamic assessment as compared to the gold-standard: invasive right heart catheterization.
Health Technology Insights: CrossMed Healthcare Staffing Appoints Amber Barna as Chief Clinical Officer
Sensydia’s CPS acquires cardiovascular signals, including heart sounds, and analyzes them using artificial intelligence algorithms, to provide clinicians a non-invasive tool for earlier assessment of cardiac function and to help them more effectively guide therapy for patients suffering from heart failure and pulmonary hypertension. The current practice to obtain these measurements is for patients to undergo echocardiography and invasive right heart catheterization, which are resource intensive, restricted to medical facilities, and only provide snapshot data. In contrast, CPS assessments are fast, safe, may be repeated as frequently as needed, and can be performed in the clinic with minimal training.
Previous studies have demonstrated the potential of CPS to accurately estimate pulmonary pressure, suggesting its utility in clinical practice. This multi-center observational study will evaluate CPS’s accuracy compared to the gold-standard invasive right heart catheterization in measuring hemodynamic parameters. The study’s outcomes will support Sensydia’s efforts toward FDA submission and commercialization of CPS.
Health Technology Insights: Precision AQ Expands Access Experience Team with Oncology Experts
“Enrolling the first patient in our pivotal study marks a significant milestone for Sensydia as we advance our mission to transform cardiac care,” said Anthony Arnold, President and CEO of Sensydia. “We believe CPS has the potential to provide clinicians with critical hemodynamic information without the risks associated with invasive procedures.”
“The ability to obtain accurate hemodynamic assessments non-invasively will significantly impact how we manage patients with heart failure and pulmonary hypertension,” said James D. Murphy, MD, FACC, Principal Investigator at the first site – Huntsville Hospital Heart Center in Alabama. “We are excited to participate in this important study evaluating CPS.”
Health Technology Insights: Orsini Launches ORBIT Track to Boost Biopharma Collaboration
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
